• Je něco špatně v tomto záznamu ?

Next Generation Sequencing Analysis and its Benefit for Targeted Therapy of Lung Adenocarcinoma

V. Kulda, J. Polivka, M. Svaton, T. Vanecek, M. Buresova, K. Houfkova, MS. Bagheri, T. Knizkova, B. Vankova, J. Windrichova, P. Macan, V. Babuska, M. Pesta

. 2023 ; 20 (4) : 404-411. [pub] -

Jazyk angličtina Země Řecko

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc23016954

BACKGROUND/AIM: Targeted therapy has become increasingly important in treating lung adenocarcinoma, the most common subtype of lung cancer. Next-generation sequencing (NGS) enables precise identification of specific genetic alterations in individual tumor tissues, thereby guiding targeted therapy selection. This study aimed to analyze mutations present in adenocarcinoma tissues using NGS, assess the benefit of targeted therapy and evaluate the progress in availability of targeted therapies over last five years. PATIENTS AND METHODS: The study included 237 lung adenocarcinoma patients treated between 2018-2020. The Archer FusionPlex CTL panel was used for NGS analysis. RESULTS: Gene variants covered by the panel were detected in 57% patients and fusion genes in 5.9% patients. At the time of the study, 34 patients (14.3% of patients) were identified with a targetable variant. Twenty-five patients with EGFR variants, 8 patients with EML4-ALK fusion and one patient with CD74-ROS1 fusion received targeted therapy. Prognosis of patients at advanced stages with EGFR variants treated by tyrosine kinase inhibitors and patients with EML4-ALK fusion treated by alectinib was significantly favorable compared to patients without any targetable variant treated by chemotherapy (p=0.0172, p=0.0096, respectively). Based on treatment guidelines applicable in May 2023, the number of patients who could profit from targeted therapy would be 64 (27.0% of patients), this is an increase by 88% in comparison to recommendations valid in 2018-2020. CONCLUSION: As lung adenocarcinoma patients significantly benefit from targeted therapy, the assessment of mutational profiles using NGS could become a crucial approach in the routine management of oncological patients.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc23016954
003      
CZ-PrNML
005      
20231026105438.0
007      
ta
008      
231013s2023 gr f 000 0|eng||
009      
AR
024    7_
$a 10.21873/cgp.20392 $2 doi
035    __
$a (PubMed)37400146
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a gr
100    1_
$a Kulda, Vlastimil $u Department of Medical Chemistry and Biochemistry, Faculty of Medicine in Pilsen, Charles University, Pilsen, Czech Republic
245    10
$a Next Generation Sequencing Analysis and its Benefit for Targeted Therapy of Lung Adenocarcinoma / $c V. Kulda, J. Polivka, M. Svaton, T. Vanecek, M. Buresova, K. Houfkova, MS. Bagheri, T. Knizkova, B. Vankova, J. Windrichova, P. Macan, V. Babuska, M. Pesta
520    9_
$a BACKGROUND/AIM: Targeted therapy has become increasingly important in treating lung adenocarcinoma, the most common subtype of lung cancer. Next-generation sequencing (NGS) enables precise identification of specific genetic alterations in individual tumor tissues, thereby guiding targeted therapy selection. This study aimed to analyze mutations present in adenocarcinoma tissues using NGS, assess the benefit of targeted therapy and evaluate the progress in availability of targeted therapies over last five years. PATIENTS AND METHODS: The study included 237 lung adenocarcinoma patients treated between 2018-2020. The Archer FusionPlex CTL panel was used for NGS analysis. RESULTS: Gene variants covered by the panel were detected in 57% patients and fusion genes in 5.9% patients. At the time of the study, 34 patients (14.3% of patients) were identified with a targetable variant. Twenty-five patients with EGFR variants, 8 patients with EML4-ALK fusion and one patient with CD74-ROS1 fusion received targeted therapy. Prognosis of patients at advanced stages with EGFR variants treated by tyrosine kinase inhibitors and patients with EML4-ALK fusion treated by alectinib was significantly favorable compared to patients without any targetable variant treated by chemotherapy (p=0.0172, p=0.0096, respectively). Based on treatment guidelines applicable in May 2023, the number of patients who could profit from targeted therapy would be 64 (27.0% of patients), this is an increase by 88% in comparison to recommendations valid in 2018-2020. CONCLUSION: As lung adenocarcinoma patients significantly benefit from targeted therapy, the assessment of mutational profiles using NGS could become a crucial approach in the routine management of oncological patients.
650    _2
$a lidé $7 D006801
650    _2
$a tyrosinkinasy $x genetika $7 D011505
650    _2
$a vysoce účinné nukleotidové sekvenování $7 D059014
650    _2
$a protoonkogenní proteiny $x genetika $7 D011518
650    12
$a adenokarcinom plic $x farmakoterapie $x genetika $7 D000077192
650    12
$a nádory plic $x farmakoterapie $x genetika $x patologie $7 D008175
650    _2
$a mutace $7 D009154
650    _2
$a tyrosinkinasové receptory $x genetika $7 D020794
650    _2
$a erbB receptory $x genetika $7 D066246
655    _2
$a časopisecké články $7 D016428
700    1_
$a Polivka, Jiri $u Department of Histology and Embryology, Faculty of Medicine in Pilsen, Charles University, Pilsen, Czech Republic $u Biomedical Center, Faculty of Medicine in Pilsen, Charles University, Pilsen, Czech Republic
700    1_
$a Svaton, Martin $u Department of Pneumology and Phthisiology, Faculty of Medicine in Pilsen, University Hospital Pilsen, Charles University, Pilsen, Czech Republic
700    1_
$a Vanecek, Tomas $u Sikl's Department of Pathology, University Hospital Pilsen, Pilsen, Czech Republic $u Biopticka laboratory s.r.o., Pilsen, Czech Republic
700    1_
$a Buresova, Marcela $u Department of Pneumology and Phthisiology, Faculty of Medicine in Pilsen, University Hospital Pilsen, Charles University, Pilsen, Czech Republic
700    1_
$a Houfkova, Katerina $u Department of Biology, Faculty of Medicine in Pilsen, Charles University, Pilsen, Czech Republic
700    1_
$a Bagheri, Mahyar Sharif $u Department of Histology and Embryology, Faculty of Medicine in Pilsen, Charles University, Pilsen, Czech Republic $u Department of Biology, Faculty of Medicine in Pilsen, Charles University, Pilsen, Czech Republic
700    1_
$a Knizkova, Tereza $u Department of Biology, Faculty of Medicine in Pilsen, Charles University, Pilsen, Czech Republic
700    1_
$a Vankova, Bohuslava $u Sikl's Department of Pathology, University Hospital Pilsen, Pilsen, Czech Republic
700    1_
$a Windrichova, Jindra $u Department of Medical Chemistry and Biochemistry, Faculty of Medicine in Pilsen, Charles University, Pilsen, Czech Republic $u Department of Immunochemical Diagnostics, University Hospital Pilsen, Pilsen, Czech Republic
700    1_
$a Macan, Petr $u Department of Surgery, University Hospital Pilsen, Pilsen, Czech Republic
700    1_
$a Babuska, Vaclav $u Department of Medical Chemistry and Biochemistry, Faculty of Medicine in Pilsen, Charles University, Pilsen, Czech Republic
700    1_
$a Pesta, Martin $u Department of Biology, Faculty of Medicine in Pilsen, Charles University, Pilsen, Czech Republic; martin.pesta@lfp.cuni.cz
773    0_
$w MED00180194 $t Cancer genomics & proteomics $x 1790-6245 $g Roč. 20, č. 4 (2023), s. 404-411
856    41
$u https://pubmed.ncbi.nlm.nih.gov/37400146 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20231013 $b ABA008
991    __
$a 20231026105433 $b ABA008
999    __
$a ok $b bmc $g 2000464 $s 1203316
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2023 $b 20 $c 4 $d 404-411 $e - $i 1790-6245 $m Cancer genomics & proteomics $n Cancer Genomics Proteomics $x MED00180194
LZP    __
$a Pubmed-20231013

Najít záznam

Citační ukazatele

Možnosti archivace